NMI Antibody (monoclonal) (M03)
Mouse monoclonal antibody raised against a partial recombinant NMI.
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IHC, E |
---|---|
Primary Accession | Q13287 |
Other Accession | BC001268 |
Reactivity | Human |
Host | mouse |
Clonality | Monoclonal |
Isotype | IgG2b Kappa |
Clone Names | 9B8 |
Calculated MW | 35057 Da |
Gene ID | 9111 |
---|---|
Other Names | N-myc-interactor, Nmi, N-myc and STAT interactor, NMI |
Target/Specificity | NMI (AAH01268, 1 a.a. ~ 100 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
Dilution | WB~~1:500~1000 |
Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
Precautions | NMI Antibody (monoclonal) (M03) is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
NMYC interactor (NMI) encodes a protein that interacts with NMYC and CMYC (two members of the oncogene Myc family), and other transcription factors containing a Zip, HLH, or HLH-Zip motif. The NMI protein also interacts with all STATs except STAT2 and augments STAT-mediated transcription in response to cytokines IL2 and IFN-gamma. The NMI mRNA has low expression levels in all human fetal and adult tissues tested except brain and has high expression in cancer cell line-myeloid leukemias.
References
New genetic associations detected in a host response study to hepatitis B vaccine. Davila S, et al. Genes Immun, 2010 Apr. PMID 20237496.Nmi (N-Myc interactor) inhibits Wnt/beta-catenin signaling and retards tumor growth. Fillmore RA, et al. Int J Cancer, 2009 Aug 1. PMID 19358268.Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. Quaye L, et al. Br J Cancer, 2009 Mar 24. PMID 19240718.Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study. Vega A, et al. Gynecol Oncol, 2009 Jan. PMID 18950845.The effects of common genetic variants in oncogenes on ovarian cancer survival. Quaye L, et al. Clin Cancer Res, 2008 Sep 15. PMID 18794094.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.